July 16, 2012 Approval Letter - VAQTA
Our STN: BL 103606/5469
Merck Sharp & Dohme Corp.
Attention: Dr. Stella Reed
UG2D-68, PO BOX 1000
North Wales, PA 19454-1099
Dear Dr. Reed:
We have approved your request to supplement your biologics license application for Hepatitis A Vaccine, Inactivated (VAQTA®), to support concomitant administration of VAQTA® with Diptheria, Tetanus, acelluar Pertussis and Haemophilus influenzae type b vaccines in 12 to 23 months old children.
The review of this product was associated with the following National Clinical Trial (NCT) number: NCT00289913.
We have completed the review of your submission and find that the following postmarketing commitments have been satisfied. The two commitments as stated in the approval letter for STN 103606/5049, dated August 11, 2005, for Hepatitis A Vaccine Inactivated, VAQTA® addressed in this submission are as follows:
#1. You have agreed to evaluate the safety of administering two doses of VAQTA six months apart in 3000 additional children 12 to 23 months of age. Overall safety and immunogenicity data in approximately 4000 children 12-23 months of age will be added to the package insert.
#4. You have agreed to conduct an open, randomized study to evaluate safety and immunogenicity of concurrent immunization of VAQTA with PedvaxHIB and concurrent immunization of VAQTA with DTaP vaccine in healthy children 15 months of age. The safety data for children administered two doses of VAQTA in this study may be included as part of your commitment to assess safety in 3000 additional children 12 to 23 months of age.
Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. In addition, please submit three original paper copies for carton and container final printed labeling. All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.
In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm1.
Information on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).
Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes this change(s).
We will include information contained in the above-referenced supplement in your biologics license application file.
Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccine
Research and Review
Center for Biologics
Evaluation and Research
Attachment: Approved Final Draft Labeling